医学
肥厚性心肌病
心脏病学
心力衰竭
内科学
心脏移植
人口
心源性猝死
移植
环境卫生
作者
Lusha W. Liang,Heidi Lumish,Lorenzo R. Sewanan,Yuichi J. Shimada,Matthew J. Maurer,Shepard D. Weiner,Gabriel Sayer,Nir Uriel,Kevin J. Clerkin
标识
DOI:10.1016/j.jchf.2023.07.004
摘要
Hypertrophic cardiomyopathy (HCM) is most commonly associated with obstructive symptoms and sudden cardiac death; however, predominantly nonobstructive advanced heart failure in HCM, marked by medically refractory disease with severe functional impairment, occurs in 5% to 7% of patients with HCM. The diagnosis relies on the integration of imaging (echocardiography/cardiac magnetic resonance), hemodynamic data, and cardiopulmonary exercise testing to identify the patients who will benefit from advanced heart failure therapies. Most advanced heart failure therapies focus on systolic dysfunction and are not always applicable to this patient population. Left ventricular assist devices may be an option in a highly selected population with left ventricular dilation. Heart transplantation is often the best option for patients with advanced heart failure in HCM with excellent post-transplantation survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI